Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

203
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
203
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

214
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
214
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

212
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
212
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

138
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
138
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

162
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
162
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of Levocarnitine.

Pharmaceutical medicine·2026
Same author

Collaborative Funding Model to Improve Quality of Care for Metastatic Breast Cancer in Europe.

Current oncology (Toronto, Ont.)·2025
Same author

Underserved Patient Populations With Metastatic Breast Cancer: A Review of Progress and Remaining Challenges.

The breast journal·2025
Same author

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial.

JNCI cancer spectrum·2024
Same author

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial.

EClinicalMedicine·2024

Related Experiment Video

Updated: Jan 8, 2026

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion
08:34

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Published on: February 24, 2021

2.9K

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim.

Pere Gascon1, Andriy Krendyukov2, Nicola Mathieson2

  • 1Division of Medical Oncology, Department of Hematology-Oncology, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|August 24, 2019
PubMed
Summary

Biosimilar filgrastim has over a decade of clinical experience, supporting its efficacy and safety across all approved indications. Real-world data and extensive patient exposure demonstrate that extrapolation is scientifically sound and effective in practice.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

16.2K

Related Experiment Videos

Last Updated: Jan 8, 2026

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion
08:34

Production of Autologous Platelet-Rich Plasma for Boosting In Vitro Human Fibroblast Expansion

Published on: February 24, 2021

2.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.2K
High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
09:00

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease

Published on: October 31, 2012

16.2K

Area of Science:

  • Biologics and biosimilars
  • Pharmacology and therapeutics
  • Oncology supportive care

Background:

  • Biosimilar filgrastim received European approval in 2009 and US approval in 2015.
  • Authorizations relied on the "totality of evidence" concept, integrating various data types.
  • Extrapolation of indications, such as for stem cell mobilization and severe chronic neutropenia, was initially based on limited clinical data.

Purpose of the Study:

  • To evaluate the long-term clinical experience and support the extrapolation of indications for biosimilar filgrastim.
  • To reassure clinicians about the efficacy and safety of biosimilar filgrastim based on accumulated evidence.
  • To highlight the scientific basis and practical effectiveness of biosimilar extrapolation.

Main Methods:

  • Review of clinical studies, including phase III trials in breast cancer patients.
  • Analysis of real-world data from the MONITOR-GCSF observational study (n=1447) in cancer patients.
  • Inclusion of data from healthy donors and patients with severe chronic neutropenia.

Main Results:

  • Over a decade of clinical use provides robust support for the totality of evidence for biosimilar filgrastim.
  • Real-world data confirm effectiveness in prophylaxis of chemotherapy-induced neutropenia.
  • Extensive patient-day exposure (over 24 million) validates the safety and efficacy of extrapolated indications.

Conclusions:

  • Accumulated clinical experience and real-world data strongly support the efficacy and safety of biosimilar filgrastim.
  • The "totality of evidence" approach, including extrapolation, is scientifically robust and effective in practice.
  • Biosimilar filgrastim is a reliable option for oncologists, supported by extensive real-world evidence.